Search results for: 'thailand in vital diagnostics market'
- Related search terms
- marketing strategy hotel industry year 1999
- vital signs the price of a good (night s) sleep insights into the us oral appliance market
- Thailand+In+Vitro+Diagnostics+Market
- Thailand++vehicle+in+last-mile+logistic+market
- market analyst of rf energy harvesting technologies
-
26 Aug 2024  |  Global  |  Market Research
Growth Opportunities in the Tissue Diagnostics Industry, Global, 2024 2029
Companion Diagnostics-specific Advanced Staining and Multiomics Capabilities are Driving Market Growth
The global tissue diagnostics market will experience significant growth driven by the need for advanced staining in precise biomarker identification in personalized medicine, tissue biopsy test volumes, and pre-analytical and advanced staining platform development. According to the WHO, there will be a 60% rise in cancer cases worldwide by 2040,...
$4,950.00 -
16 Jan 2024  |  Global  |  Market Research
Top 5 Growth Opportunities for Clinical Diagnostics, 2024
Enabling Precision Health Journey Through Omics, Digital Diagnostics Services, and Smart Screening Solutions
Clinical diagnostics is undergoing a radical shift, driven by omics integration for precision health, digital diagnostics services, and smart screening solutions. Digital diagnostics are streamlining data analysis and communication, and enhancing overall efficiency. Smart screening, powered by AI and machine learning, is ensuring early and accurate...
$2,450.00 -
25 Mar 2026  |  Global  |  Market Research
Global Clinical Diagnostics Industry Growth Opportunities, 2026–2031
Next-Gen AI-Integrated Biomarkers and Smart Automation are Advancing Precision and Early Detection in Molecular and Point-of-Care Diagnostics
The global clinical diagnostics market is poised for strong growth, driven by increased adoption of advanced diagnostics technologies, greater investment in laboratories, and improved access to molecular and immunodiagnostic testing facilities. In 2025, the industry continued its transformation, establishing testing systems as intelligent systems...
$4,950.00 -
09 Jul 2025  |  Global  |  Market Outlook
Global Clinical Diagnostics Outlook, 2025
Driven by Novel Biomarkers, Digital Services, and Automation, Industry is Accelerating Precision, Efficiency, and Early Disease Detection in Molecular Diagnostics and Point-of-care Testing (POCT)
The global clinical diagnostics market is poised for strong growth as stakeholders shift focus toward high-growth segments such as precision medicine, decentralized diagnostics, software-driven solutions, and product expansion. Companies continue to adopt LIMS and other digital platforms while emerging opportunities in the POCT sector further drive...
$4,950.00 -
25 Aug 2026  |  Global  |  Technology Research
Breakthrough Innovations in Point-of-Care Diagnostics
Rapid Molecular Platforms, AI-Powered Workflows, Home-Based Testing, and Connected Care Models to Drive Decentralized Diagnostics
This research analyzes how point-of-care (PoC) diagnostics is evolving from simple tests to decentralized, connected, and clinically actionable testing platforms across hospitals, outpatient settings, homes, and pharmacies.The study assesses key technology shifts, including rapid molecular testing, lateral flow assays, microfluidics, biosensors, sm...
$4,950.00 -
31 Jul 2023  |  North America  |  Market Research
Global Oncology Diagnostics in IVD Growth Opportunities
By Leveraging Data-driven Solutions, Co-development Opportunities, and Assay Innovation, Clients Can Experience Enhanced Product Performance, Cost-effectiveness, and Improved Decision-making Capabilities
The global oncology diagnostics in IVD market is expected to witness significant growth, driven by an increase in cancer incidence, technological developments in diagnostic tests, the growing number of screening tests, and supportive government initiatives. Owing to the intense competition in the market, the most prominent companies are investing h...
$4,950.00 -
24 Feb 2016  |  North America  |  Market Research
US Autoimmune Disease Diagnostics Market, Forecast to 2020
Systemic Autoimmune Diseases to Spur Double-digit Market Growth as Participants Look to Unmet Needs and Game-changing Strategies to Boost Revenues
According to the National Institute of Health (NIH), there are more than 80 types of autoimmune diseases, of which less than 30 are diagnosable. Being 1 of the top 10 causes of death in the United States, there is a critical need in the market for the diagnosis and the treatment of both systemic diseases, such as lupus and rheumatoid arthritis, as ...
$1,500.00 -
27 Aug 2026  |  Global  |  Frost Radar
Frost Radar: AI-Powered Molecular Diagnostics, 2026
A Benchmarking System to Spark Companies to Action - Innovation That Fuels New Deal Flow and Growth Pipelines
AI-powered molecular diagnostics is an emerging and moderately fragmented industry that includes molecular diagnostics companies, precision medicine platforms, sequencing specialists, AI-driven analytics providers, and disease-focused biotechnology companies. No single company has dominated, presenting opportunities for innovation. There has been a...
$4,950.00 -
03 Jan 2022  |  Global  |  Technology Research
AI Augmentation in Molecular Diagnostics
AI Applications to improve predictive, diagnostic, and prognostic value of molecular diagnostics
This Frost & Sullivan research service discusses advances in AI integration in Molecular Diagnostics, highlights key advantages of incorporating AI in the diagnostics workflow and roadblocks that have prevented it from becoming mainstream. While AI is widely used in radiology- and pathology-based diagnostics, its adoption is gradually increasing in...
$4,950.00 -
13 Dec 2022  |  Global  |  Technology Research
Companion Diagnostics (CDx): Technology Innovation and Growth Opportunities
The Transition to Precision Medicine is Propelling the Adoption of CDx Platforms.
The concept of companion diagnostics (CDx) was developed when researchers realized that even potent drugs only had an efficacy between 25% and 60%, the lowest being in oncology. Therefore, a clinical pharmacogenetic assay became important to distinguish patients more likely to respond to a drug or at a lesser risk of associated adverse pathophysiol...
$4,950.00